Monte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - Slideshow

Monte Rosa Therapeutics presented its latest research at the 2026 AACR Annual Meeting, showcasing advancements in targeted protein degradation therapies for cancer and other diseases. The company’s slide deck highlighted preclinical and clinical progress in its molecular glue degrader (MGD) platform, designed to selectively eliminate disease-causing proteins. Key data included updates on lead candidates targeting previously undruggable proteins, emphasizing potential first-in-class therapies for oncology and autoimmune disorders. Investor and scientific interest focused on the platform’s precision and scalability, with implications for next-generation drug development beyond traditional small-molecule approaches. The presentation underscored Monte Rosa’s pipeline expansion, with plans to advance multiple programs into clinical trials by late 2026.